Michael D Tarantino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2427795/publications.pdf

Version: 2024-02-01

27 papers 3,144 citations

687220 13 h-index 26 g-index

27 all docs

27 docs citations

times ranked

27

2457 citing authors

#	Article	IF	CITATIONS
1	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) – Unmet needs remain. Haemophilia, 2022, 28, 453-461.	1.0	5
2	Characterization of Laboratory Coagulation Parameters and Risk Factors for Intraventricular Hemorrhage in Extremely Premature Neonates. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	1
3	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). Haemophilia, 2021, 27, 49-59.	1.0	6
4	Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency. Haemophilia, 2021, 27, 531-543.	1.0	5
5	Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia. Journal of Clinical Medicine, 2021, 10, 2471.	1.0	47
6	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Reviews, 2021, 49, 100811.	2.8	9
7	Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. Blood Advances, 2021, 5, 4969-4979.	2.5	2
8	Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. Journal of Medical Economics, 2020, 23, 184-192.	1.0	29
9	The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States. Platelets, 2020, 31, 307-314.	1.1	10
10	Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Pediatric Blood and Cancer, 2020, 67, e28630.	0.8	6
11	Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. Haematologica, 2019, 104, 2283-2291.	1.7	27
12	Central venous access device catheter fragmentation at time of removal in four patients with haemophilia A. Haemophilia, 2019, 25, e185-e188.	1.0	O
13	Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion, 2019, 17, 479-486.	0.3	53
14	Risk factors associated with intraventricular hemorrhage in extremely premature neonates. Blood Coagulation and Fibrinolysis, 2018, 29, 25-29.	0.5	19
15	Immune Thrombocytopenia in US Clinical Practice: Incidence and Healthcare Utilization/Expenditures in the First 12 Months Following Diagnosis. Blood, 2018, 132, 2239-2239.	0.6	3
16	Hemophilia Management via Data Collection and Reporting: Initial Findings from the Comprehensive Care Sustainability Collaborative. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 51-56.	0.5	3
17	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet, The, 2016, 388, 45-54.	6.3	116
18	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. Platelets, 2016, 27, 472-478.	1.1	14

#	Article	IF	CITATION
19	Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Platelets, 2015, 26, 93-96.	1.1	13
20	Romiplostim as a treatment for immune thrombocytopenia: a review. Journal of Blood Medicine, 2015, 6, 37.	0.7	22
21	Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. Acta Haematologica, 2015, 134, 215-228.	0.7	22
22	Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag. Platelets, 2014, 25, 55-61.	1.1	11
23	Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2013, 24, 284-296.	0.5	9
24	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	0.6	1,802
25	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, The, 2008, 371, 395-403.	6.3	784
26	Single dose of anti-D immune globulin at $75\hat{l}\frac{1}{4}g/kg$ is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. Journal of Pediatrics, 2006, 148, 489-494.	0.9	104
27	The Child With Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management?. Journal of Pediatric Hematology/Oncology, 2004, 26, 146-151.	0.3	22